Stock AnalizAmgen (AMGN) earnings for the quarter ended September 2026: EPS beats estimates
Amgen reported results for the quarter ended September 2026 on November 3, 2026. Adjusted earnings per share came in at $6.45 against the analysts’ average forecast of $5.78, a beat of 11.6%.
Revenue for the quarter was $10.37 billion, up 8.5% from $9.56 billion in the same quarter a year earlier.
The market’s verdict: the stock rose 2.8% on the first trading day after the report.
The last four quarters
Amgen has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $6.45 | $5.78 | +11.6% | +8% | +2.8% |
| Jun 2026 | $6.29 | $5.62 | +12.0% | +10% | +7.6% |
| Mar 2026 | $5.15 | $4.77 | +8.0% | +6% | −2.4% |
| Dec 2025 | $5.29 | $4.73 | +11.9% | +9% | +6.2% |
What comes next
Analysts expect EPS of $5.64 for the next quarter on average and $23.52 for the fiscal year ending December 31, 2026.
The average analyst price target is $431.81, 7% below the current price of $465.67.
Valuation and score
Amgen scores 2.4 out of 5 overall on Stock Analiz (average), trades at a trailing P/E of about 27.0, and its intrinsic value under moderate assumptions is about 26% below the current market value. Full Amgen analysis with 10 years of financials
Frequently asked questions
What was Amgen’s EPS for the quarter ended September 2026?
$6.45 adjusted per share, against an analyst consensus of $5.78.
How much revenue did Amgen report?
$10.37 billion, up 8.5% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.